Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

BACKGROUND: Interleukin-2 (IL-2) induces durable objective responses in a small cohort of patients with metastatic renal cell carcinoma (RCC) but the antigen(s) responsible for tumor rejection are not known. 5T4 is a non-secreted membrane glycoprotein expressed on clear cell and papillary RCCs. A mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Howard L, Taback, Bret, Sherman, William, Kim, Dae Won, Shingler, William H, Moroziewicz, Dorota, DeRaffele, Gail, Mitcham, Josephine, Carroll, Miles W, Harrop, Richard, Naylor, Stuart, Kim-Schulze, Seunghee
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631474/
https://www.ncbi.nlm.nih.gov/pubmed/19128501
http://dx.doi.org/10.1186/1479-5876-7-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631474/
https://www.ncbi.nlm.nih.gov/pubmed/19128501
http://dx.doi.org/10.1186/1479-5876-7-2

Ejemplares similares